glp-1 atrial fibrillation Receptor Agonists in Heart Failure GLP-1 Receptor Agonists and Myocardial

For Canadian patients exploring GLP-1 options, genetic insights combined with clinical evaluation can support a more personalized conversation with your healthcare provider about which GLP-1 formulation, dose pathway, and monitoring strategy may be most appropriate for your individual situation

This is in line with the ACSM recommendations to replace sodium losses after two hours of exercise or exercise that results in heavy sweating

Sinai Hospital receives grant support from Amgen, Eli Lilly and Zealand Pharma for preclinical studies in the laboratory of D.J.D

A 2024 study published in JAMA Ophthalmology reported that patients with Type 2 diabetes who took semaglutide-containing medications had more than a fourfold higher risk for developing non-arteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist